Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183-97.Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment ...
CAR-T细胞疗法在实体瘤研究中面临的挑战 嵌合抗原受体 (CAR) T 细胞是经过基因工程改造的 T 细胞，可表达用于识别特定肿瘤标志物的受体，从而实现对血液肿瘤的治疗。目前全球已有7种获批上市的CAR-T细胞疗法，适应症均为血液瘤，且有多项CAR-T疗法的临床试验正在进行。然而，CAR-T细胞疗法仍存在重大的局限性，包括...
Validire, P., Trautmann, A., ... & Donnadieu, E. (2012). Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. The Journal of clinical investigation, 122(3), 899-910. ...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-38...
Successful implementation of adoptive cell therapy (ACT) of cancer requires comprehensively addressing biological and practical challenges. This approach has been largely overlooked, resulting in a gap between the potential of ACT and its actual effectiveness. We summarize the most promising technical ...
The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and...
2024年3月28日,《细胞》(Cell)发布了中山肿瘤防治中心徐瑞华教授等人的一篇综述《Challenges and opportunities in oncology drug development and clinical research in China》,指出目前在全球临床试验版图中,中国已占据了近1/3的比例。 ...
3月7日,最新发表在Nature Medicine杂志上的一项研究显示,由美国City of Hope开展的一项用于治疗胶质母细胞瘤的开创性I期试验(NCT02208362)显示,CAR-T细胞疗法对这类极具侵袭性的脑肿瘤显示出良好的临床活性。据称,这是迄今为止报道的最大的CAR-T治疗实体瘤的试验。
CAR-T疗法属于过继性T细胞转移(adoptive T-cell transfer,ACT)的一种,CAR-T细胞技术的核心为能够通过将识别肿瘤相关抗原(TAA)的scFv和胞内信号域“免疫受体酪氨酸活化基序”(ITAM,通常为CD3ζ)在体外进行基因重组,生成重组质粒,再在体外通过转染技术转染到患者的T细胞,使患者T细胞表达肿瘤抗原受体。 转染后经过纯化和...
CAR-T疗法发展历程 CAR-T疗法属于过继性T细胞转移(adoptive T-cell transfer,ACT)的一种,CAR-T细胞技术的核心为能够通过将识别肿瘤相关抗原(TAA)的scFv和胞内信号域“免疫受体酪氨酸活化基序”(ITAM,通常为CD3ζ)在体外进行基因重组,生成重组质粒,再在体外通过转染技术转染到患者的T细胞,使患者T细胞表达肿瘤抗原受体...